Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3158-3161
10.1182/blood-2022-158248